On March 26, 2025 Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, reported that it will present results of 6 studies as poster presentation at the AACR (Free AACR Whitepaper) Annual Meeting to be held in Chicago, USA, from April 25-30, 2025 (Press release, Mabwell Biotech, MAR 26, 2025, View Source [SID1234651484]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The AACR (Free AACR Whitepaper) Annual Meeting is one of the largest cancer research conferences in the world. The abstracts have been published on the AACR (Free AACR Whitepaper) official website.

#01
Title: A B7-H3-targeting antibody-drug conjugate, 7MW3711, and PARP inhibitors synergistically potentiate the antitumor activity in B7-H3-positive cancers
Published Abstract Number: 830
Location: Poster Section 34
Poster Board Number: 18
Session Date and Time: Apr. 27, 2025 2:00 PM-5:00 PM (local time)

#02
Title: Design and synthesis of the novel camptothecin analog MF6 for application into site-specific antibody-drug conjugate
Published Abstract Number: 5733
Location: Poster Section 25
Poster Board Number: 4
Session Date and Time: Apr. 29, 2025 2:00 PM-5:00 PM (local time)

#03
Title: MW-C01/C02, novel CLDN1-targeting antibody-drug conjugates, demonstrate compelling anti-tumor efficacy and favorable safety profiles in preclinical studies
Published Abstract Number: 1573
Location: Poster Section 15
Poster Board Number: 22
Session Date and Time: Apr. 28, 2025 9:00 AM-12:00 PM (local time)

#04
Title: 2MW7061, a novel LILRB4xCD3 bispecific T-cell engager targeting monocytic acute myeloid leukemia
Published Abstract Number: 2116
Location: Poster Section 34
Poster Board Number: 2
Session Date and Time: Apr. 28, 2025 9:00 AM-12:00 PM (local time)

#05
Title: An innovative T cell engager platform with optimized CD3 affinity and formats for targeting hematologic and solid tumors
Published Abstract Number: 2866
Location: Poster Section 15
Poster Board Number: 5
Session Date and Time: Apr. 28, 2025 2:00 PM-5:00 PM (local time)

#06
Title: 7MW4911, a novel cadherin 17-targeting ADC, demonstrates potent efficacy in preclinical models of gastrointestinal cancers
Published Abstract Number: 5466
Location: Poster Section 15
Poster Board Number: 24
Session Date and Time: Apr. 29, 2025 2:00 PM-5:00 PM (local time)